ACTU (Actuate Therapeutics) Days Payable : 0.00 (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Actuate Therapeutics Days Payable?

Actuate Therapeutics's average Accounts Payable for the three months ended in Dec. 2024 was $2.13 Mil. Actuate Therapeutics's Cost of Goods Sold for the three months ended in Dec. 2024 was $0.00 Mil.

The historical rank and industry rank for Actuate Therapeutics's Days Payable or its related term are showing as below:

ACTU's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 124.08
* Ranked among companies with meaningful Days Payable only.

Actuate Therapeutics's Days Payable stayed the same from Dec. 2023 (0.00) to Dec. 2024 (0.00). stayed the same

Actuate Therapeutics Days Payable Historical Data

The historical data trend for Actuate Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actuate Therapeutics Days Payable Chart

Actuate Therapeutics Annual Data

Trend

Dec22

Dec23

Dec24

Days Payable

Actuate Therapeutics Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Days Payable	Get a 7-Day Free Trial				-	-	-	-	-

Competitive Comparison of Actuate Therapeutics's Days Payable

For the Biotechnology subindustry, Actuate Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Actuate Therapeutics's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actuate Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Actuate Therapeutics's Days Payable falls into.

Save Embed

;

Save Embed

;

Actuate Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Actuate Therapeutics's Days Payable for the fiscal year that ended in Dec. 2024 is calculated as

	Days Payable (A: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2023 )	+	Accounts Payable (A: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2024 )	*	Days in Period
=	( (3.422	+	1.921)	/	2 )	/	0	*	365
=	2.6715					/	0	*	365
=	N/A

Actuate Therapeutics's Days Payable for the quarter that ended in Dec. 2024 is calculated as:

	Days Payable (Q: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2024 )	+	Accounts Payable (Q: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2024 )	*	Days in Period
=	( (2.33	+	1.921)	/	2 )	/	0	*	365 / 4
=	2.1255					/	0	*	365 / 4
=	N/A

Actuate Therapeutics Days Payable Related Terms

Thank you for viewing the detailed overview of Actuate Therapeutics's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Actuate Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actuate Therapeutics Inc (NAS:ACTU) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

1751 River Run, Suite 400, Fort Worth, TX, USA, 76107

Website

https://www.actuatetherapeutics.com

Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.